At MediMix, we are dedicated to keeping Belgian healthcare professionals at the forefront of medicine. Our team brings you high-value insights from leading congresses worldwide, across key disease areas including hematology. In collaboration with Belgian and international experts, we transform the latest data into practical knowledge.
During the 2025 IMS meeting, Prof Dr Marie-Christiane Vekemans shared the real-world experience with teclistamab in the treatment of relapsed/refractory multiple myeloma (RRMM) patients across three centres in Belgium
During the 2025 IMS meeting in Toronto, Prof Dr Sigurdur Kristinsson gave an educational talk on the factors determining the risk of progression, apart from genetics and the microenvironment.
In the plenary session of IMS 2025, Dr Ludovic Martinet presented the result of his research into the response of the immune system following quadruplet therapy in multiple myeloma (MM)
During IMS 2025, Prof Dr Vania Hungria presented the results of a subgroup analysis of this trial, focussing on lenalidomide-refractory patients. The results in this subgroup were in line with
According to Prof Claudio Cerchione these findings are highly relevant—particularly given the growing role of isatuximab in the evolving therapeutic landscape of multiple myeloma.
At the 2025 annual IMS meeting, several presentations highlighted the use of the new on-body injector (OBI) designed to facilitate the administration of the subcutaneous (SC) formulation of isatuximab. In
During the 2025 IMS meeting, Dr Lisa Leypoldt, haematologist at the University Medical Center in Hamburg addressed the critical topic of patient preferences at relapse in multiple myeloma care.
At the 2025 IMS meeting, Prof Dr Jesús San-Miguel presented a new analysis evaluating the impact of MRD negativity on patients treated in the pivotal PERSEUS and CEPHEUS studies. In
